RESEARCH PAPER

Metallomics and Genomics Integration: The Role of ICP-MS and ICP-OES in Genetic Disease Research

S. Likitha[1], K. Pavan Kumar[1], N. Pujitha[1], K. Maneesh Kumar Reddy[1], C. T. Manjunath[1], M. Mohan Reddy[1], P. Mounika[1], K. Vinod Kumar[1*]

[1] Department of Pharmaceutical Analysis, Raghavendra Institute of Pharmaceutical Education and Research, K. R. Palli, Chiyyedu, Ananthapur, Andhra Pradesh - 515721.

[*] **Corresponding Author:** Dr. K. Vinod Kumar, Professor, Department of Pharmaceutical Analysis, Raghavendra Institute of Pharmaceutical Education and Research, K. R. Palli, Chiyyedu, Anantapur, Andhra Pradesh - 515721.
Email: vinodpharma@gmail.com Mobile: 9989071070

ABSTRACT

Genetic disorders involving metal metabolism dysregulation pose significant challenges in diagnosis, treatment, and monitoring. Traditional diagnostic methods, such as genetic sequencing and biochemical assays, often fail to detect early metabolic imbalances, delaying interventions. Inductively Coupled Plasma (ICP) Spectroscopy, including ICP-Mass Spectrometry (ICP-MS) and ICP-Optical Emission Spectroscopy (ICP-OES), has emerged as a highly sensitive and precise tool for analyzing trace metal concentrations in biological samples, offering new insights into metal-associated genetic disorders.

This article explores the role of ICP spectroscopy in early diagnosis, biomarker discovery, and treatment monitoring for disorders such as Wilson's disease (copper accumulation), hemochromatosis (iron overload), Menkes disease (copper deficiency), and lead poisoning-related neurodevelopmental disorders. ICP-MS enables the detection of ultra-trace metal levels, ensuring early intervention before clinical symptoms appear. Additionally, ICP techniques facilitate personalized medicine approaches, allowing for individualized treatment plans based on a patient's metal homeostasis profile.

Recent advancements in HR-ICP-MS, single-cell ICP-MS, and laser ablation ICP-MS have further expanded the applications of ICP spectroscopy in genomic and proteomic research, enabling detailed elemental mapping and improved disease modelling. The integration of ICP spectroscopy with omics technologies is paving the way for precision medicine, optimizing treatments for genetic disorders at an individualized level.

As ICP technology continues to evolve, it holds immense potential for advancing genetic disorder research, improving diagnostic accuracy, and enhancing therapeutic strategies, ultimately transforming the landscape of metallomics-based medicine.

Keywords: ICP Spectroscopy, ICP-OES, Genetic Disorders, Metal Metabolism, Elemental Analysis, Metal Toxicity

How to cite this article: Likitha S, Kumar KP, Pujitha N, Reddy KMR, Manjunath CT, Reddy MM, Mounika P, Kumar KV. Metallomics and Genomics Integration: The Role of ICP-MS and ICP-OES in Genetic Disease Research. Int J Drug Deliv Technol. 2026;16(22s): 520-532. DOI: 10.25258/ijddt.16.22s.64

Source of support: Nil.

Conflict of interest: None

1. Introduction

Genetic disorders are a diverse group of medical conditions caused by abnormalities in an individual's DNA[1]. These disorders may result from gene mutations, chromosomal alterations, or inherited genetic defects, leading to significant health complications[2]. Many genetic disorders are linked to imbalances in essential trace elements, such as copper, iron, and zinc, which play crucial roles in biological processes. For instance, Wilson's disease results from excessive copper accumulation, while hemochromatosis leads to excessive iron deposition in tissues. Understanding and accurately detecting these metal imbalances is vital for diagnosing and managing such conditions. For instance, Wilson's disease results from excessive copper accumulation, while hemochromatosis leads to excessive iron deposition in tissues[3]. Understanding and accurately detecting these metal imbalances is vital for diagnosing and managing such conditions[4].

This technique provides high sensitivity, precision, and the ability to analyze multiple elements simultaneously, making it particularly useful in studying genetic disorders related to metal metabolism. ICP-Optical Emission Spectroscopy (ICP-OES) and ICP-Mass Spectrometry (ICP-MS) are widely employed in biomedical research to measure trace metal concentrations in blood, urine, and tissues. These methods help in early diagnosis, disease progression monitoring, and assessing treatment efficacy[5].

With advancements in technology, ICP spectroscopy is increasingly integrated with genomics and bioinformatics to enhance diagnostic accuracy and personalized treatment approaches. However, challenges such as sample preparation complexities, cost, and potential interferences remain areas of ongoing research. As precision medicine continues to evolve, ICP spectroscopy is expected to play an even greater role in understanding and managing genetic disorders associated with metal ion imbalances[6].

This article explores the significance of ICP spectroscopy in studying genetic disorders, its applications in medical diagnostics, and future prospects in biomedical research.

1.1 Overview of Genetic Disorders

Genetic disorders are medical conditions caused by abnormalities in an individual's DNA. These abnormalities can occur due to mutations in a single gene (monogenic disorders),changes in multiple genes (polygenic disorders), or chromosomal abnormalities such as deletions, duplications, or translocations[7]. Genetic disorders can be inherited from parents or arise spontaneously due to mutations during cell division. Monogenic disorders are caused by mutations in a single gene and follow Mendelian inheritance patterns[8]. Examples include cystic fibrosis, which affects the respiratory and digestive systems, sickle cell anemia, which alters red blood cell shape, and Huntington's disease, a neurodegenerative condition. These disorders can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner[9].

Polygenic disorders result from mutations in multiple genes, often influenced by environmental factors. Examples include diabetes, heart disease, and certain types of cancer. These disorders are more complex, as both genetic predisposition and lifestyle factors contribute to their development[10].

Chromosomal disorders occur when there are structural or numerical abnormalities in chromosomes[11]. Conditions such as Down syndrome (trisomy 21), Turner syndrome (missing an X chromosome in females), and Klinefelter syndrome (extra X chromosome in males) fall under this category. These disorders can cause developmental delays, intellectual disabilities, and physical abnormalities[12].

Some genetic disorders also involve metal ion imbalances, such as Wilson's disease (copper accumulation) and hemochromatosis (iron overload). Detecting these abnormalities is crucial for early diagnosis and treatment[3]. Advanced techniques like Inductively Coupled Plasma (ICP) spectroscopy help in analyzing trace elements in biological samples, offering valuable insights into genetic diseases[13].

Understanding genetic disorders is essential for early detection, personalized treatment, and potential gene therapies, paving the way for improved healthcare outcomes.

1.2 Importance of Trace Element Analysis in Genetic Diseases

Trace elements, such as iron, copper, zinc, manganese, and selenium, play crucial roles in various biological processes, including enzyme function, metabolism, and cellular signaling[14]. An imbalance in these essential elements can lead to severe health complications, especially in individuals with genetic disorders. Accurate trace element analysis is vital for diagnosing, managing, and understanding the progression of genetic diseases[15].

Several genetic disorders are directly linked to trace element dysregulation. Wilson's disease, for instance, results from mutations in the ATP7B gene, leading to excessive copper accumulation in the liver and brain, causing liver damage and neurological symptoms[16]. Similarly, Menkes disease is caused by mutations in the ATP7A gene, resulting in copper deficiency, which leads to severe developmental delays and connective tissue abnormalities[17]. Hemochromatosis, an iron overload disorder due to mutations in the HFE gene, can cause organ failure if untreated[18].

Trace element analysis helps in early diagnosis, allowing timely intervention before irreversible damage occurs[19]. Techniques such as Inductively Coupled Plasma (ICP) spectroscopy, including ICP-Optical Emission Spectroscopy (ICP-OES) and ICP-Mass Spectrometry (ICP-MS), provide highly sensitive and accurate measurements of metal ion concentrations in biological samples such as blood, urine, and tissues[20]. These methods enable monitoring disease progression and evaluating treatment effectiveness, such as the success of chelation therapy in Wilson's disease[21].

Furthermore, studying trace elements aids in identifying biomarkers for genetic diseases, facilitating early screening in at-risk populations[22]. As precision medicine advances, integrating trace element analysis with genomic data will enhance personalized treatment approaches, improving patient outcomes and quality of life[23]. Thus, trace element analysis remains a fundamental tool in genetic disease research and clinical diagnostics.

1.3 Role of Inductively Coupled Plasma (ICP) Spectroscopy in Biomedical Research

Inductively Coupled Plasma (ICP) spectroscopy is a powerful analytical technique used in biomedical research for detecting and quantifying trace elements in biological samples. It plays a crucial role in understanding disease mechanisms, diagnosing genetic disorders, and monitoring treatment responses[24]. ICP spectroscopy is widely used in analyzing metals and other elements in blood, urine, tissues, and other biological fluids, providing valuable insights into various medical conditions[25].

One of the key applications of ICP spectroscopy in biomedical research is in the diagnosis and study of genetic disorders related to metal metabolism. Conditions such as Wilson's disease (copper accumulation), Menkes disease (copper deficiency), and hemochromatosis (iron overload) require precise measurement of trace elements for early detection and management[3]. ICP-Optical Emission Spectroscopy (ICP-OES) and ICP-Mass Spectrometry (ICP-MS) enable highly sensitive and accurate detection of these metal imbalances, aiding in disease identification and monitoring[26].

Additionally, ICP spectroscopy is essential in pharmacokinetics and toxicology studies, helping researchers understand how drugs interact with trace elements in the body. It is also used in biomarker discovery, where researchers analyze elemental composition to identify early indicators of diseases such as cancer, neurodegenerative disorders, and metabolic conditions[27].

Another critical role of ICP spectroscopy is in nutritional and environmental health studies. Researchers use it to examine deficiencies or toxicities of essential elements like zinc, selenium, and lead, contributing to public health improvements[28].

As biomedical research advances, the integration of ICP spectroscopy with genomic and proteomic studies is enhancing precision medicine approaches, allowing for personalized diagnostics and targeted therapies[29]. The high sensitivity, accuracy, and multi-element capabilities of ICP spectroscopy make it an indispensable tool in modern biomedical science[30].

2. Understanding Inductively Coupled Plasma (ICP) Spectroscopy

2.1 Principles of ICP Spectroscopy

Inductively Coupled Plasma (ICP) Spectroscopy is an advanced analytical technique used to measure the concentration of elements in biological, environmental, and industrial samples. It is widely applied in medical diagnostics, toxicology, and biochemical research due to its high sensitivity and precision[31].

The technique involves ionizing a sample using a plasma source—typically generated by radiofrequency energy applied to argon gas. This high-energy plasma (7000–10,000 K) breaks down the sample into individual atoms and ions, which emit light at characteristic wavelengths or generate a mass-to-charge ratio. These emissions are then analyzed to determine the elemental composition and concentration within the sample[32].

ICP spectroscopy is particularly useful in genetic disorder research because it provides quantitative analysis of trace metals, which are often involved in metabolic pathways and enzymatic reactions[33]. For instance, abnormal levels of copper, iron, or zinc in biological fluids can indicate metabolic disorders linked to gene mutations. Traditional biochemical assays detect proteins or metabolites, but ICP allows for precise, multi-elemental analysis, improving diagnostic accuracy[34].

Furthermore, ICP spectroscopy can detect elements at concentrations as low as parts per trillion (ppt), making it an invaluable tool for studying early-stage metabolic imbalances in genetic diseases. Its ability to analyze a wide range of elements in a single run makes it highly efficient for biomedical research, clinical diagnostics, and pharmacology[4].

2.1.1 Types of ICP Techniques: ICP-OES vs. ICP-MS

Inductively Coupled Plasma (ICP) Spectroscopy is broadly classified into two main techniques: ICP-Optical Emission Spectroscopy (ICP-OES) and ICP-Mass Spectrometry (ICP-MS). Each has unique advantages depending on the sensitivity, accuracy, and type of sample analysis required[35].

2.1.2 ICP-Optical Emission Spectroscopy (ICP-OES)

ICP-OES, also known as ICP-Atomic Emission Spectroscopy (ICP-AES), measures the light emitted by excited atoms in a sample when exposed to a high-temperature plasma. This emitted light corresponds to

specific wavelengths that identify and quantify each element[36].

Advantages:

Suitable for analyzing high-concentration elements (e.g., iron, copper, zinc).

Faster and cost-effective compared to ICP-MS.

Can analyse multiple elements simultaneously[37].

Limitations:

Less sensitive for ultra-trace element detection (ppt levels).

Overlapping emission lines can sometimes affect accuracy[38].

2.2 ICP-Mass Spectrometry (ICP-MS)

ICP-MS detects elements based on their mass-to-charge ratio (m/z). It is significantly more sensitive than ICP-OES, allowing for ultra-trace analysis (down to ppt levels)[39].

Advantages:

Extremely high sensitivity, ideal for detecting metals in genetic disorders.

Can measure isotopic ratios, useful for studying metal metabolism.

Less interference compared to ICP-OES[13].

Limitations:

More expensive and requires specialized operation.

Prone to polyatomic interferences, which may require correction techniques

ICP-OES is preferred for routine metal analysis, while ICP-MS is used for highly sensitive, in-depth studies—making both techniques indispensable in genetic disorder research[40].

2.3 The Role of Metals in Genetic Disorders

Metals are essential to various biological processes, including enzyme function, cellular signaling, and gene regulation. The human body tightly regulates trace elements such as iron (Fe), copper (Cu), zinc (Zn), selenium (Se), and manganese (Mn) to maintain metabolic balance. However, genetic mutations affecting metal metabolism can lead to severe disorders, including neurodegenerative, metabolic, and developmental conditions[41].

Genetic disorders often disrupt metal transport, storage, or excretion, causing either toxic accumulation or deficiency. For instance, excess iron in hemochromatosis damages vital organs, while copper accumulation in Wilson's disease leads to liver and neurological damage[42]. Similarly, copper deficiency in Menkes disease results in severe neurodevelopmental impairment. Lead poisoning, although primarily an environmental concern, can induce epigenetic mutations and is linked to neurodevelopmental disorders[43].

ICP spectroscopy plays a vital role in detecting and quantifying these metal imbalances. Unlike traditional blood tests, ICP can measure ultra-trace metal concentrations in biological fluids and tissues, allowing for early diagnosis and disease monitoring[34]. For example, ICP-MS detects elevated copper levels in Wilson's disease or reduced iron in certain anemias, providing critical diagnostic information[3].

Additionally, ICP spectroscopy supports biomarker discovery for genetic disorders, identifying metal-based signatures that help predict disease progression. By offering highly precise elemental analysis, ICP techniques significantly enhance our understanding of how genetic mutations impact metal metabolism and pave the way for targeted therapeutic strategies[44].

2.3.1 Wilson's Disease (Copper Accumulation)

Wilson's disease is a genetic disorder of copper metabolism caused by mutations in the ATP7B gene, which encodes a copper-transporting ATPase in the liver[45]. This mutation impairs copper excretion into bile, leading to toxic accumulation in the liver, brain, and kidneys. Without treatment, Wilson's disease can cause liver failure, neurological impairments, and psychiatric symptoms[46].

Patients typically exhibit hepatic dysfunction (jaundice, cirrhosis), neurological symptoms (tremors, dystonia), and Kayser-Fleischer rings—copper deposits in the cornea[47]. Traditional diagnostic tests include serum ceruloplasmin levels, 24-hour urine copper excretion, and liver biopsy, but these methods can be invasive and lack precision. ICP spectroscopy, particularly ICP-MS, offers a more accurate and non-invasive alternative for copper quantification[48].

ICP-MS detects copper at trace levels in blood, urine, and hair samples, distinguishing Wilson's disease from other liver disorders[49]. Unlike conventional tests, ICP can measure free serum copper, the most toxic form responsible for neurological damage. Additionally, ICP-OES can analyze hepatic copper content in biopsy samples, aiding in disease staging[50].

ICP spectroscopy also plays a role in treatment monitoring. Wilson's disease is managed with chelating agents (penicillamine, trientine) and zinc therapy to reduce copper overload. ICP techniques help track copper levels over time, ensuring therapeutic effectiveness[51].

By enabling precise elemental analysis, ICP spectroscopy enhances the diagnosis and management of Wilson's disease, offering a reliable method to detect copper dysregulation before irreversible organ damage occur[48].

2.3.2 Hemochromatosis (Iron Overload)

Hemochromatosis is a genetic disorder of iron metabolism characterized by excessive iron absorption from the diet, leading to iron overload in organs such as the liver, heart, pancreas, and joints[52]. The most common form, hereditary hemochromatosis (HH), is caused by mutations in the HFE gene, particularly the C282Y and H63D variants. This mutation disrupts the regulation of hepcidin, the hormone responsible for controlling iron absorption, leading to uncontrolled iron accumulation[53].

Excess iron generates reactive oxygen species (ROS), causing oxidative stress and damage to vital organs[54]. If left untreated, hemochromatosis can result in liver cirrhosis, diabetes, cardiomyopathy, arthritis, and increased cancer risk. Traditional diagnostic methods include serum ferritin, transferrin saturation tests, and liver biopsies, but these have limitations in early detection[55].

ICP spectroscopy, particularly ICP-OES and ICP-MS, provides precise quantification of iron levels in blood, serum, and tissue samples[56]. Unlike conventional tests, ICP techniques can detect ultra-trace levels of iron, distinguishing between normal, deficient, and toxic concentrations. ICP-MS is especially useful for analyzing isotopic variations of iron, which helps in studying disease progression and therapeutic responses[57].

Treatment for hemochromatosis involves regular phlebotomy (blood removal) and iron chelation therapy. ICP spectroscopy is valuable in monitoring iron levels during treatment, ensuring patients maintain safe iron concentrations[58]. Early detection via ICP spectroscopy allows for timely intervention, preventing irreversible organ damage and improving patient outcomes[59].

2.3.3 Menkes Disease (Copper Deficiency)

Menkes disease is a rare X-linked genetic disorder caused by mutations in the ATP7A gene, which encodes a copper-transporting ATPase essential for copper absorption and distribution[60]. This mutation leads to impaired copper transport, causing severe copper deficiency in key organs such as the brain, liver, and bones while paradoxically allowing excess copper accumulation in the intestines and kidneys[61].

Copper is crucial for enzymatic reactions, connective tissue development, neurological function, and energy metabolism[62]. A deficiency disrupts multiple physiological processes, leading to intellectual disability, growth retardation, brittle hair (kinky hair disease), hypotonia, seizures, and vascular abnormalities. Symptoms typically appear in infancy, and without early intervention, the disease is often fatal within the first few years of life[63].

Traditional diagnostic methods include serum copper and ceruloplasmin tests, but these can be inconsistent and unreliable in early disease stages[64]. ICP-MS and ICP-OES provide more accurate and sensitive detection of copper levels in blood, cerebrospinal fluid, and hair samples[65]. ICP-MS, in particular, can detect trace copper concentrations at the parts-per-trillion (ppt) level, enabling earlier and more precise diagnosis[34].

Treatment involves copper histidine injections, which can improve neurological outcomes if started early. ICP spectroscopy plays a crucial role in monitoring copper levels during therapy, ensuring optimal dosing and preventing toxicity[66]. By enabling precise copper quantification, ICP techniques significantly enhance early detection, treatment monitoring, and research on Menkes disease, ultimately improving patient survival and quality of life[67].

2.3.4 Lead Poisoning and Neurodevelopmental Disorders

Lead poisoning is a toxicological condition with significant genetic and neurodevelopmental implications. Unlike Wilson's or Menkes disease, which are hereditary disorders, lead poisoning results from environmental exposure but can induce epigenetic changes, leading to neurodevelopmental disorders such as autism, ADHD, and cognitive impairments[68]. Lead (Pb) is a heavy metal with no biological function, and its accumulation in the body, particularly in children, disrupts brain development, neurotransmitter function, and DNA expression[69].

Chronic lead exposure affects gene regulation by altering DNA methylation and histone modifications, which can cause long-term neurological deficits. Lead interferes with calcium-dependent cellular processes, leading to learning disabilities, reduced IQ, memory deficits, and behavioral disorders. High lead levels also inhibit heme synthesis, causing anemia and oxidative stress[70].

ICP spectroscopy, especially ICP-MS, is the gold standard for detecting ultra-trace levels of lead in blood, urine, hair, and tissues[71]. Unlike conventional blood tests, which may fail to detect low but harmful lead levels, ICP-MS provides ppt-level sensitivity, ensuring early diagnosis even at subclinical exposure levels. This is

crucial because even low-level lead exposure can cause irreversible brain damage in children[72].

Treatment involves chelation therapy using agents like EDTA and dimercaptosuccinic acid (DMSA), which bind lead and facilitate its excretion. ICP spectroscopy is essential for monitoring lead levels during treatment, ensuring effective detoxification[73]. By offering precise elemental analysis, ICP techniques aid in early detection, risk assessment, and treatment of lead-induced neurodevelopmental disorders, helping to prevent lifelong cognitive impairments[69].

2.4 ICP Spectroscopy in Genetic Disorder Diagnosis and Research

Inductively Coupled Plasma (ICP) Spectroscopy has emerged as a powerful tool in diagnosing and researching genetic disorders by enabling precise elemental analysis of biological samples[13]. Many genetic disorders involve dysregulation of trace metals, such as copper, iron, zinc, and lead, which affect metabolism, enzymatic activity, and cellular signaling. ICP spectroscopy provides a highly sensitive and quantitative approach to detecting these imbalances, making it invaluable for early diagnosis, disease monitoring, and biomarker discovery[42].

Traditional diagnostic methods, such as genetic sequencing and biochemical assays, focus on DNA mutations or protein dysfunction but often fail to detect early metabolic disturbances[74]. ICP techniques, particularly ICP-MS and ICP-OES, bridge this gap by identifying abnormal metal concentrations before symptoms fully manifest[75]. For example, elevated copper levels in Wilson's disease or increased iron in hemochromatosis can be detected before organ damage occurs, allowing for timely intervention[76].

Beyond diagnosis, ICP spectroscopy is crucial for biomedical research and pharmacogenomics. Researchers use ICP to study metal-dependent enzymes, oxidative stress markers, and the impact of metal-based drugs in genetic disorders. Isotopic analysis via ICP-MS further aids in understanding metal metabolism, toxicokinetics, and gene-environment interactions[77].

By integrating ICP spectroscopy with genomics, proteomics, and metabolomics, scientists can develop novel therapeutic strategies and personalized medicine approaches. The ability of ICP to provide multi-elemental analysis with extreme sensitivity makes it an indispensable tool in the future of genetic disorder diagnostics and research[78].

2.5 Early Diagnosis and Biomarker Discovery Using ICP-MS

Early diagnosis is crucial in genetic disorders to prevent irreversible damage and improve treatment outcomes. Traditional diagnostic methods, such as genetic testing and biochemical assays, often detect disease only after symptoms appear[74]. ICP-MS (Inductively Coupled Plasma Mass Spectrometry) provides a more sensitive and precise approach by identifying metal imbalances associated with genetic disorders before clinical symptoms manifest[79].

ICP-MS enables ultra-trace metal detection at parts-per-trillion (ppt) levels, making it ideal for early-stage diagnosis[80]. For instance, in Wilson's disease, ICP-MS can detect elevated free copper in blood or urine long before liver damage occurs. Similarly, in hemochromatosis, it can measure subtle increases in iron levels, allowing for pre-symptomatic screening. This early detection is critical for initiating preventive treatments such as chelation therapy or dietary modifications[81].

Another major application of ICP-MS is biomarker discovery. Researchers use ICP-MS to analyze biological fluids (blood, urine, cerebrospinal fluid) and tissues to identify metal-based biomarkers linked to genetic disorders. For example, alterations in zinc and selenium levels have been associated with neurodevelopmental disorders, including autism spectrum disorder (ASD). Additionally, isotopic analysis with ICP-MS helps distinguish toxic metal exposure (e.g., lead poisoning) from genetic metal metabolism disorders[82].

By combining ICP-MS with genomic and proteomic studies, scientists can develop personalized medicine approaches, tailoring treatments based on an individual's metal metabolism profile. This integration of elemental and molecular data paves the way for next-generation diagnostics in genetic disorders.

2.6 Monitoring Treatment and Disease Progression with ICP-OES and ICP-MS

Accurate monitoring of treatment response and disease progression is essential in managing genetic disorders affecting metal metabolism. Inductively Coupled Plasma techniques, particularly ICP-OES (Optical Emission Spectroscopy) and ICP-MS (Mass Spectrometry), provide real-time, quantitative analysis of metal levels in biological samples, ensuring optimal therapeutic management[83].

For patients with Wilson's disease, ICP-MS is used to monitor serum and urinary copper levels during chelation

therapy with penicillamine or trientine. Maintaining copper balance is crucial to prevent toxicity while ensuring essential functions remain intact. Similarly, in hemochromatosis, ICP-OES tracks iron concentrations in blood and tissues during phlebotomy treatment, ensuring patients do not develop iron deficiency anemia due to overcorrection[84].

ICP spectroscopy is also instrumental in evaluating drug efficacy and toxicity. For example, patients undergoing zinc therapy for Wilson's disease require careful monitoring to avoid secondary deficiencies in other trace elements like iron and selenium. ICP-MS can detect these subtle changes, allowing for dose adjustments to maintain overall metabolic balance[85].

Additionally, ICP techniques help assess disease progression by measuring metal accumulation in different tissues over time. In Menkes disease, ICP-MS can evaluate the effectiveness of copper histidine injections by monitoring copper uptake in the brain. In lead poisoning cases, ICP-MS ensures that detoxification therapies (e.g., EDTA chelation) are effectively reducing toxic lead levels[86].

By integrating ICP-OES and ICP-MS into routine clinical monitoring, healthcare providers can optimize treatment plans, minimize side effects, and improve long-term patient outcomes in genetic disorders related to metal dysregulation.

2.7 Future Prospects of ICP Spectroscopy in Genetic Disorder Research

The future of ICP spectroscopy in genetic disorder research is highly promising, as advancements in technology, sensitivity, and multi-elemental analysis continue to drive the field forward. One of the most exciting prospects is the integration of ICP techniques with other diagnostic tools, such as genomics, metabolomics, and proteomics, to create a more holistic approach to understanding genetic diseases. This integration will allow researchers to explore how genetic mutations impact metal metabolism on a molecular level, providing new insights into the pathophysiology of disorders like Wilson's disease, hemochromatosis, and Menkes disease[42].

Future developments in ICP-MS and ICP-OES technologies will enhance detection limits and resolution, enabling the identification of even trace levels of metals in complex biological matrices. This will be crucial for early-stage detection of diseases before they manifest clinically. Additionally, advances in sample preparation techniques will allow for more efficient analysis of hard-to-reach biological samples, such as brain tissue, expanding the scope of research into neurological and neurodegenerative disorders[87].

Another promising area is the application of ICP spectroscopy for personalized medicine. As genetic and environmental factors influence metal homeostasis, ICP techniques could help tailor treatment regimens based on an individual's metal profile, optimizing therapeutic strategies. This could lead to more effective and individualized treatments, particularly for conditions that require lifelong management, like Wilson's disease[77].

Furthermore, real-time monitoring using portable ICP devices may revolutionize clinical practice, enabling non-invasive, point-of-care testing for metal imbalances. This would make early intervention more accessible, especially in remote or resource-limited areas[88].

In summary, the future of ICP spectroscopy lies in its ability to integrate with cutting-edge technologies, enhancing diagnostic accuracy, treatment monitoring, and personalized therapeutic strategies, ultimately advancing the field of genetic disorder research.

2.8 Advancements in ICP Technology for Biomedical Applications

The continuous evolution of Inductively Coupled Plasma (ICP) technology is revolutionizing biomedical applications, particularly in genetic disorder research. Modern developments in ICP-MS (Mass Spectrometry) and ICP-OES (Optical Emission Spectroscopy) have significantly improved sensitivity, precision, and multi-element analysis capabilities, making these techniques indispensable for studying metal-related genetic disorders[89].

One of the most notable advancements is the introduction of High-Resolution ICP-MS (HR-ICP-MS), which provides greater mass separation, reducing spectral interferences and allowing for ultra-trace metal detection in complex biological samples. This is particularly useful for analyzing minute changes in metal concentrations in neurodegenerative and metabolic disorders[90].

Another Additionally, laser ablation ICP-MS (LA-ICP-MS) has gained traction in biomedical imaging, allowing for elemental mapping of tissues with unprecedented spatial resolution. This technique can track metal deposition in the brain, liver, and kidneys, providing new insights into disease mechanisms and progression[91].

Advancements in automation and miniaturization are also making ICP spectroscopy more accessible in clinical settings, enabling faster diagnostics and real-time monitoring of metal imbalances. As these innovations

continue to develop, ICP technology will play a pivotal role in early disease detection, personalized medicine, and novel therapeutic strategies for genetic disorders.

2.9 Integration of ICP Spectroscopy with Genomic and Proteomic Studies

The integration of ICP spectroscopy with genomic and proteomic studies is transforming our understanding of genetic disorders involving metal metabolism. While genomics focuses on DNA mutations and proteomics examines protein expression and function, ICP-MS and ICP-OES provide essential insights into how trace metal imbalances influence these biological processes[6]. By combining these techniques, researchers can better characterize disease mechanisms, identify biomarkers, and develop targeted therapies. One key application is in metallo-genomics, where ICP spectroscopy helps identify how genetic mutations impact metal-binding proteins. For instance, mutations in ATP7B (Wilson's disease) or ATP7A (Menkes disease) affect copper transport, leading to either accumulation or deficiency. ICP-MS quantifies copper levels in tissues and biofluids, correlating them with gene expression data to understand disease progression[92].

In proteomic studies, ICP spectroscopy aids in the identification of metalloproteins, which play crucial roles in cellular processes. Techniques such as LC-ICP-MS (Liquid Chromatography coupled with ICP-MS) allow for the separation and quantification of metal-bound proteins, revealing how metal dysregulation contributes to diseases like neurodegenerative disorders and cancer[93].

Furthermore, integrating ICP-MS with mass spectrometry-based proteomics (e.g., LC-MS/MS) enhances our ability to discover metal-based biomarkers, leading to more accurate diagnostic tools and personalized treatment strategies. This interdisciplinary approach is paving the way for precision medicine, where therapies are tailored based on an individual's genetic profile and metal metabolism status[94].

By bridging the gap between elemental analysis and molecular biology, the fusion of ICP spectroscopy with genomics and proteomics is accelerating breakthroughs in genetic disorder research and treatment development.

2.10 Potential for Personalized Medicine and Targeted Therapies Using ICP Spectroscopy

Personalized medicine aims to tailor treatments based on an individual's genetic makeup, metabolic profile, and environmental factors. ICP spectroscopy, particularly ICP-MS and ICP-OES, plays a crucial role in this field by providing precise elemental analysis, allowing clinicians to customize treatments for patients with genetic disorders affecting metal metabolism.

One major application of ICP spectroscopy in personalized medicine is in therapeutic monitoring. For example, patients with Wilson's disease require life-long chelation therapy to remove excess copper. However, over-chelation can lead to copper deficiency, causing neurological complications. ICP-MS allows real-time monitoring of copper levels in blood and urine, enabling dose adjustments to maintain an optimal balance. Similarly, in hemochromatosis, ICP-OES helps regulate iron removal through phlebotomy, preventing both overload and deficiency[95].

Another promising area is targeted drug development. By analyzing metal-protein interactions, ICP techniques help design metal-based drugs that selectively bind to disease-related molecules. This is particularly useful for conditions like neurodegenerative disorders, where metal dysregulation contributes to disease progression. For instance, ICP-MS can guide the development of iron-chelating agents for Parkinson's and Alzheimer's disease, optimizing their effectiveness while minimizing side effects[96].

Moreover, integrating ICP spectroscopy with genomic and proteomic data allows for a more comprehensive understanding of individual variability in metal metabolism. This paves the way for precision medicine approaches, where treatments are tailored not just to a disease but to the unique biochemical profile of each patient[97].

As ICP technology advances, it will continue to revolutionize personalized medicine, improving treatment efficacy, minimizing adverse effects, and enhancing patient outcomes.

Conclusion

The integration of Inductively Coupled Plasma (ICP) Spectroscopy in the study of genetic disorders has revolutionized our ability to diagnose, monitor, and develop treatments for diseases involving metal metabolism dysregulation. By providing highly sensitive, multi-elemental analysis, ICP-MS and ICP-OES have emerged as indispensable tools in clinical and research settings, offering unparalleled precision in detecting trace metal imbalances.

This article, we explored how ICP techniques contribute to the early diagnosis of genetic disorders such as

Wilson's disease, hemochromatosis, and Menkes disease, enabling timely interventions before irreversible organ damage occurs. Additionally, ICP-MS plays a crucial role in biomarker discovery, identifying metal-based indicators that improve diagnostic accuracy and treatment planning. Furthermore, ICP spectroscopy facilitates treatment monitoring, ensuring that therapeutic interventions such as chelation therapy and metal supplementation are effectively tailored to each patient's needs.

The future of ICP spectroscopy in genetic disorder research is incredibly promising. Advancements in HR-ICP-MS, single-cell ICP-MS, and laser ablation ICP-MS will enhance our understanding of metal-based pathophysiology at the cellular and tissue levels. The integration of ICP spectroscopy with genomic and proteomic studies is paving the way for personalized medicine, where treatments are customized based on an individual's genetic and metabolic profile. As technology continues to evolve, ICP spectroscopy will remain at the forefront of biomedical research, offering novel insights into metal-associated genetic disorders and driving innovations in diagnostics, therapeutics, and precision medicine.

Acknowledgement:

The authors express their sincere gratitude to Raghavendra Institute of Pharmaceutical Education and Research (RIPER) Autonomous, Anantapur, Andhra Pradesh, India, for providing for their valuable suggestions and encouragement throughout the preparation of this manuscript.

Conflict of Interest:

The authors declare that they have no conflict of interest.

Reference:

(1) Mahdieh, N.; Rabbani, B. An overview of mutation detection methods in genetic disorders. *Iranian journal of pediatrics* **2013**, *23* (4), 375.

(2) Samir, S. Human DNA mutations and their impact on genetic disorders. *Recent Patents on Biotechnology* **2024**, *18* (4), 288–315.

(3) Teschke, R.; Eickhoff, A. Wilson disease: copper-mediated cuproptosis, iron-related ferroptosis, and clinical highlights, with comprehensive and critical analysis update. *International journal of molecular sciences* **2024**, *25* (9), 4753.

(4) López-Alonso, M.; Rivas, I.; Miranda, M. Trace mineral imbalances in global health: Challenges, Biomarkers, and the role of serum analysis. *Nutrients* **2025**, *17* (13), 2241.

(5) Vanhaecke, F.; Costas-Rodríguez, M. High-precision isotopic analysis of essential mineral elements: capabilities as a diagnostic/prognostic tool. *View* **2021**, *2* (1), 20200094.

(6) Zhang, Y.; Xu, Y.; Zheng, L. Disease ionomics: understanding the role of ions in complex disease. *International Journal of Molecular Sciences* **2020**, *21* (22), 8646.

(7) Hoedemaekers, R.; ten Have, H. The concept of abnormality in medical genetics. *Theoretical Medicine and Bioethics* **1999**, *20* (6), 537–561.

(8) Germain, D. P.; Jurca-Simina, I. E. Principles of human genetics and Mendelian inheritance. In *Neurometabolic hereditary diseases of adults*, Springer, 2018; pp 1–28.

(9) Din, S. M. U.; Fatima, H.; Haq, E. U.; Ullah, K.; Rasheed, M. U.; Aziz, T. The Genetics and Pathophysiology of Single Gene Disorders in Human. *Integrated Health and Sustainability: Plants, Wildlife, and Genetic Resilience*, 210.

(10) Visscher, P. M.; Yengo, L.; Cox, N. J.; Wray, N. R. Discovery and implications of polygenicity of common diseases. *Science* **2021**, *373* (6562), 1468–1473.

(11) Theisen, A.; Shaffer, L. G. Disorders caused by chromosome abnormalities. *The application of clinical genetics* **2010**, 159–174.

(12) Bihunyak, T. V.; Bondarenko, Y. I.; Kulyanda, O. O.; Charnosh, S. M.; Sverstiuk, A. S.; Bihuniak, K. Chromosomal diseases in the human pathology. *International Journal of Medicine and Medical Research (IJMMR)* **2020**, *1* (6), 50–60.

(13) Michalke, B. Review about powerful combinations of advanced and hyphenated sample introduction techniques with inductively coupled plasma-mass spectrometry (ICP-MS) for elucidating trace element species in pathologic conditions on a molecular level. *International Journal of Molecular Sciences* **2022**, *23* (11), 6109.

(14) Prashanth, L.; Kattapagari, K. K.; Chitturi, R. T.; Baddam, V. R. R.; Prasad, L. K. A review on role of essential trace elements in health and disease. *Journal of dr ntr university of health sciences* **2015**, *4* (2), 75–85.

(15) Patriarca, M.; Menditto, A.; Di Felice, G.; Petrucci, F.; Caroli, S.; Merli, M.; Valente, C. Recent developments in trace element analysis in the prevention,

diagnosis, and treatment of diseases. *Microchemical journal* **1998**, *59* (2), 194–202.
(16) Dong, J.; Xiang, G.; Xia, X.; Xu, L.; Wen, P.; Xu, C.; Xu, Y.; Su, Y.; Song, Y.; Tong, H. Aberrant copper metabolism and hepatic inflammation cause neurological manifestations in a mouse model of Wilson's disease. *Journal of Neuroinflammation* **2024**, *21* (1), 235.
(17) Lenartowicz, M.; Krzeptowski, W.; Lipiński, P.; Grzmil, P.; Starzyński, R.; Pierzchała, O.; Møller, L. B. Mottled mice and non-mammalian models of Menkes disease. *Frontiers in Molecular Neuroscience* **2015**, *8*, 72.
(18) Katsarou, M.-S.; Papasavva, M.; Latsi, R.; Drakoulis, N. Hemochromatosis: hereditary hemochromatosis and HFE gene. *Vitamins and hormones* **2019**, *110*, 201–222.
(19) Taylor, A. Detection and monitoring of disorders of essential trace elements. *Annals of clinical biochemistry* **1996**, *33* (6), 486–510.
(20) Olesik, J. W. Elemental analysis using icp-oes and icp/ms. *Analytical Chemistry* **1991**, *63* (1), 12A–21A.
(21) Shribman, S.; Poujois, A.; Bandmann, O.; Czlonkowska, A.; Warner, T. T. Wilson's disease: update on pathogenesis, biomarkers and treatments. *Journal of Neurology, Neurosurgery & Psychiatry* **2021**, *92* (10), 1053–1061.
(22) Nazir, A.; Nazir, A.; Afzaal, U.; Aman, S.; Sadiq, S. u. R.; Akah, O. Z.; Jamal, M. S. W.; Hassan, S. Z. Advancements in biomarkers for early detection and risk stratification of cardiovascular diseases—a literature review. *Health Science Reports* **2025**, *8* (5), e70878.
(23) Strianese, O.; Rizzo, F.; Ciccarelli, M.; Galasso, G.; D'Agostino, Y.; Salvati, A.; Del Giudice, C.; Tesorio, P.; Rusciano, M. R. Precision and personalized medicine: how genomic approach improves the management of cardiovascular and neurodegenerative disease. *Genes* **2020**, *11* (7), 747.
(24) Islam, Z.; Aslam, M.; Khan, A. U.; ur Rehman, M. Genetic Testing and its Role in Precision Medicine: Understand Disease Risk and Tailoring Treatments. *Indus Journal of Bioscience Research* **2025**, *3* (1), 461–470.
(25) Taylor, A.; Barlow, N.; Day, M. P.; Hill, S.; Martin, N.; Patriarca, M. Atomic Spectrometry Update: review of advances in the analysis of clinical and biological materials, foods and beverages. *Journal of Analytical Atomic Spectrometry* **2019**, *34* (3), 426–459.
(26) Patriarca, M.; Barlow, N.; Cross, A.; Hill, S.; Robson, A.; Tyson, J. Atomic spectrometry update: review of advances in the analysis of clinical and biological materials, foods and beverages. *Journal of Analytical Atomic Spectrometry* **2023**, *38* (3), 496–577.
(27) Ahmad, A.; Imran, M.; Ahsan, H. Biomarkers as biomedical bioindicators: approaches and techniques for the detection, analysis, and validation of novel biomarkers of diseases. *Pharmaceutics* **2023**, *15* (6), 1630.
(28) Plum, L. M.; Rink, L.; Haase, H. The essential toxin: impact of zinc on human health. *International journal of environmental research and public health* **2010**, *7* (4), 1342–1365.
(29) Ikwelle, T. A.; Ihim, A. C.; Ozuruoke, D. F.; Obi, P. C.; Obi, C. U.; Onuora, I. J.; Chimezie, A. J.; Romanus, O. O. Multi-Omics Integration in Personalized Medicine: Advancing Laboratory Diagnostics and Precision Therapeutics in the Era of Individualized Healthcare. *Journal of Drug Delivery & Therapeutics* **2025**, *15* (5).
(30) Sawicki, J.; Feldo, M.; Skalska-Kamińska, A.; Sowa, I. Modern Bioimaging Techniques for Elemental Tissue Analysis: Key Parameters, Challenges and Medical Impact. *Molecules* **2025**, *30* (13), 2864.
(31) Dean, J. R. *Practical inductively coupled plasma spectrometry*; John Wiley & Sons, 2019.
(32) Ciopec, M.; Pascu, B.; Negrea, P. Inductively coupled plasma optical spectroscopy and atomic absorption spectroscopy. *Microbial Electrochemical Technologies: Fundamentals and Applications* **2023**, *1*, 201–228.
(33) Sanz-Medel, A.; Montes-Bayón, M.; Luisa Fernández Sánchez, M. Trace element speciation by ICP-MS in large biomolecules and its potential for proteomics. *Analytical and Bioanalytical Chemistry* **2003**, *377* (2), 236–247.
(34) SHAIKH, F. M. R.; UZGARE, A. S. Tracing elements with precision: A review of inductively coupled plasma mass spectrometry (ICP-MS). *International Journal of Chemistry Research* **2026**, 26–34.
(35) Ghosh, S.; Prasanna, V. L.; Sowjanya, B.; Srivani, P.; Alagaraja, M.; Banji, D. Inductively coupled plasma–optical emission spectroscopy: a review. *Asian Journal of Pharmaceutical Analysis* **2013**, *3* (1), 24–33.
(36) Brittle, S. W.; Baker, J. D.; Dorney, K. M.; Dagher, J. M.; Ebrahimian, T.; Higgins, S. R.; Pavel Sizemore, I. E. Measuring the silver composition of nanocolloids by inductively coupled plasma–optical emission spectroscopy: A laboratory experiment for chemistry and engineering students. *Journal of Chemical Education* **2015**, *92* (6), 1061–1065.

(37) Carter, S.; Clough, R.; Fisher, A.; Gibson, B.; Russell, B. Atomic spectrometry update: review of advances in the analysis of metals, chemicals and materials. *Journal of Analytical Atomic Spectrometry* **2021**, *36* (11), 2241–2305.
(38) Bulska, E.; Ruszczyńska, A. Analytical techniques for trace element determination. *Physical Sciences Reviews* **2017**, *2* (5), 20178002.
(39) Huang, M.; Li, X. Quantitative Detection of Toxic Elements in Food Samples by Inductively Coupled Plasma Mass Spectrometry (ICP-MS). *Processes* **2025**, *13* (10).
(40) Limbeck, A.; Bonta, M.; Nischkauer, W. Improvements in the direct analysis of advanced materials using ICP-based measurement techniques. *Journal of Analytical Atomic Spectrometry* **2017**, *32* (2), 212–232.
(41) Jomova, K.; Alomar, S. Y.; Valko, R.; Nepovimova, E.; Kuca, K.; Valko, M. The role of redox-active iron, copper, manganese, and redox-inactive zinc in toxicity, oxidative stress, and human diseases. *EXCLI journal* **2025**, *24*, 880.
(42) Umair, M.; Alfadhel, M. Genetic disorders associated with metal metabolism. *Cells* **2019**, *8* (12), 1598.
(43) Zlatic, S.; Comstra, H. S.; Gokhale, A.; Petris, M. J.; Faundez, V. Molecular basis of neurodegeneration and neurodevelopmental defects in Menkes disease. *Neurobiology of disease* **2015**, *81*, 154–161.
(44) Zang, Z.; Liu, X.; Wang, M.; Wang, Z. The Application of Inductively Coupled Plasma Mass Spectrometry in Cancer Research. *Critical Reviews in Analytical Chemistry* **2025**, *55* (6), 1233–1257.
(45) Wu, F.; Wang, J.; Pu, C.; Qiao, L.; Jiang, C. Wilson's disease: a comprehensive review of the molecular mechanisms. *International journal of molecular sciences* **2015**, *16* (3), 6419–6431.
(46) Tao, T. Y.; Gitlin, J. D. Hepatic copper metabolism: insights from genetic disease. *Hepatology* **2003**, *37* (6), 1241–1247.
(47) Prasad, D.; Bhriguvanshi, A. Ocular manifestations of liver disease in children: Clinical aspects and implications. *Annals of Hepatology* **2020**, *19* (6), 608–613.
(48) Kumar, J.; Roy, I. Advancements in diagnostic approaches for Wilson's disease. *Analytical Methods* **2025**, *17* (21), 4228–4250.
(49) Weiskirchen, S.; Kim, P.; Weiskirchen, R. Determination of copper poisoning in Wilson's disease using laser ablation inductively coupled plasma mass spectrometry. *Annals of Translational Medicine* **2019**, *7* (Suppl 2), S72.
(50) Susnea, I.; Weiskirchen, R. Trace metal imaging in diagnostic of hepatic metal disease. *Mass Spectrometry Reviews* **2016**, *35* (6), 666–686.
(51) Weiskirchen, R. Comprehensive Pharmacological Management of Wilson's Disease: Mechanisms, Clinical Strategies, and Emerging Therapeutic Innovations. *Sci* **2025**, *7* (3), 94.
(52) Milman, N. T. Managing genetic hemochromatosis: an overview of dietary measures, which may reduce intestinal iron absorption in persons with iron overload. *Gastroenterology research* **2021**, *14* (2), 66.
(53) Anderson, G. J.; Bardou-Jacquet, E. Revisiting hemochromatosis: genetic vs. phenotypic manifestations. *Annals of translational medicine* **2021**, *9* (8), 731.
(54) Gammella, E.; Recalcati, S.; Cairo, G. Dual role of ROS as signal and stress agents: iron tips the balance in favor of toxic effects. *Oxidative medicine and cellular longevity* **2016**, *2016* (1), 8629024.
(55) Ahmed, S.; Peterson, S. J.; Parikh, M. A.; Frishman, W. H. Cardiovascular manifestations of hemochromatosis: a review of pathophysiology, mechanisms, and treatment options. *Cardiology in Review* **2025**, *33* (4), 359–364.
(56) Harrington, J. M.; Young, D. J.; Essader, A. S.; Sumner, S. J.; Levine, K. E. Analysis of human serum and whole blood for mineral content by ICP-MS and ICP-OES: development of a mineralomics method. *Biological trace element research* **2014**, *160* (1), 132–142.
(57) Fagieh, T. M. ICP-MS Determination of Zn, Cu, Fe and Mn in muscle cells as potential markers of oxidative stress. Loughborough University, 2017.
(58) Barton, J. C.; McDonnell, S. M.; Adams, P. C.; Brissot, P.; Powell, L. W.; Edwards, C. Q.; Cook, J. D.; Kowdley, K. V.; Group*, H. M. W. Management of hemochromatosis. *Annals of internal medicine* **1998**, *129* (11_Part_2), 932–939.
(59) Ko, T. S.; Catennacio, E.; Shin, S. S.; Stern, J.; Massey, S. L.; Kilbaugh, T. J.; Hwang, M. Advanced neuromonitoring modalities on the horizon: detection and management of acute brain injury in children. *Neurocritical care* **2023**, *38* (3), 791–811.
(60) Mercer, J. F. The molecular basis of copper-transport diseases. *Trends in molecular medicine* **2001**, *7* (2), 64–69.

(61) Chen, J.; Jiang, Y.; Shi, H.; Peng, Y.; Fan, X.; Li, C. The molecular mechanisms of copper metabolism and its roles in human diseases. *Pflügers Archiv-European Journal of Physiology* **2020**, *472* (10), 1415–1429.
(62) An, Y.; Li, S.; Huang, X.; Chen, X.; Shan, H.; Zhang, M. The role of copper homeostasis in brain disease. *International journal of molecular sciences* **2022**, *23* (22), 13850.
(63) Simpson, K. L. Syndromes and inborn errors of metabolism. *Children with disabilities* **2013**, 757–801.
(64) Aboalam, H. S.; Hassan, M. K.; El-Domiaty, N.; Ibrahim, N. F.; Ali, A. M.; Hassan, W.; El Wafa, E. G. A.; Elsaghier, A.; Hetta, H. F.; Elbadry, M. Challenges and recent advances in diagnosing Wilson disease. *Journal of Clinical and Experimental Hepatology* **2025**, *15* (4), 102531.
(65) Ha, Y.; Tsay, O. G.; Churchill, D. G. A tutorial and mini-review of the ICP-MS technique for determinations of transition metal ion and main group element concentration in the neurodegenerative and brain sciences. *Monatshefte für Chemie-Chemical Monthly* **2011**, *142* (4), 385–398.
(66) Rafati Rahimzadeh, M.; Rafati Rahimzadeh, M.; Kazemi, S.; Moghadamnia, A. A. Copper poisoning with emphasis on its clinical manifestations and treatment of intoxication. *Advances in Public Health* **2024**, *2024* (1), 6001014.
(67) e Vairo, F. P.; Chwal, B. C.; Perini, S.; Ferreira, M. A. P.; de Freitas Lopes, A. C.; Saute, J. A. M. A systematic review and evidence-based guideline for diagnosis and treatment of Menkes disease. *Molecular genetics and metabolism* **2019**, *126* (1), 6–13.
(68) Khalid, M.; Abdollahi, M. Epigenetic modifications associated with pathophysiological effects of lead exposure. *Journal of Environmental Science and Health, Part C* **2019**, *37* (4), 235–287.
(69) Sanders, T.; Liu, Y.; Buchner, V.; Tchounwou, P. B. Neurotoxic effects and biomarkers of lead exposure: a review. *Reviews on environmental health* **2009**, *24* (1), 15.
(70) Elsweedy, S. A.; Khodaery, M. F.; Abdelkader, A.; Shaarawy, N. I. An Overview of Lead-Induced Neurotoxicity. *Biannual Forensic Sciences and Toxicology Journal* **2024**, *2* (1), 31–56.
(71) Taylor, A.; Catchpole, A.; Day, M. P.; Hill, S.; Martin, N.; Patriarca, M. Atomic spectrometry update: review of advances in the analysis of clinical and biological materials, foods and beverages. *Journal of Analytical Atomic Spectrometry* **2020**, *35* (3), 426–454.
(72) Abduljabbar, T. N. Bio-imaging and serum analysis of zinc and other trace elements in a study of age-related diseases using inductively-coupled plasma mass spectrometry. Loughborough University, 2018.
(73) Nielsen, P. Chelation therapy for heavy metals. **2016**.
(74) Korf, B. R.; Rehm, H. L. New approaches to molecular diagnosis. *Jama* **2013**, *309* (14), 1511–1521.
(75) Ebrahimi, P.; Barbieri, M. Gadolinium as an emerging microcontaminant in water resources: threats and opportunities. *Geosciences* **2019**, *9* (2), 93.
(76) Roberts, E. A.; Schilsky, M. L. Diagnosis and treatment of Wilson disease: an update. *Hepatology* **2008**, *47* (6), 2089–2111.
(77) Lachowicz, J. I.; Lecca, L. I.; Meloni, F.; Campagna, M. Metals and metal-nanoparticles in human pathologies: From exposure to therapy. *Molecules* **2021**, *26* (21), 6639.
(78) Carter, S.; Clough, R.; Fisher, A.; Gibson, B.; Russell, B. Atomic spectrometry update: review of advances in the analysis of metals, chemicals and materials. *Journal of Analytical Atomic Spectrometry* **2022**, *37* (11), 2207–2281.
(79) Yang, H. S.; LaFrance, D. R.; Hao, Y. Elemental testing using inductively coupled plasma mass spectrometry in clinical laboratories: an ACLPS critical review. *American Journal of Clinical Pathology* **2021**, *156* (2), 167–175.
(80) Hernández-Montoya, D. A.; Castañeda-Miranda, A. G.; Martinez-Fierro, M. L.; Talavera-Lopez, A.; Sandoval-Arechiga, R.; Gómez-Rodríguez, J. R.; Rodríguez-Abdalá, V. I.; Castañeda-Miranda, R.; Flores-Chaires, L. A.; Vázquez-Reyes, S. Heavy Metal Contamination in Foods: Advances in Detection Technologies, Regulatory Challenges, and Health Risks. **2026**.
(81) Patch, C. Comparison of two screening strategies for haemochromatosis: a pilot study investigating uptake and acceptability, feasibility and cost. University of Southampton, 2003.
(82) Baj, J.; Kowalska, B.; Barbachowska, A.; Forma, A.; Flieger, M.; Majerek, D.; Teresiński, G.; Flieger, W.; Portincasa, P.; Buszewicz, G. Linking metallic micronutrients and toxic xenobiotics to atherosclerosis and fatty liver Disease—Postmortem ICP-MS analysis of selected human tissues. *Nutrients* **2023**, *15* (15), 3458.
(83) Kadhim, I. M. H.; Miteb, T. T. Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Instrumentation, Analysis, Strengths, Limitations, Biomedical and

Pharmaceutical Applications. *Clinical Images and Case Reports* **2024**, *2* (06), 22–42.
(84) Álvarez, S. I.; Marcén, J. F. E. 1. General characteristics of trace elements: Diagnostic algorithms and methods in clinical laboratory.
(85) García-Poyo, M. C. New analytical approaches for copper diagnosis, prognosis and follow up of Wilson disease. Université de Pau et des Pays de l'Adour, 2021.
(86) Ferreira, C. R.; Gahl, W. A. Disorders of metal metabolism. *Translational science of rare diseases* **2017**, *2* (3-4), 101–139.
(87) Preetam, S.; Lata, S.; Bora, J.; Thapliyal, S.; Mehta, S.; Ramniwas, S.; Deshwal, R.; Rustagi, S.; Talukdar, N.; Malik, S. Exosome-driven biohybrid nanorobots: bridging nature and nanotechnology in biomedical innovation. *RSC advances* **2025**, *15* (40), 33390–33409.
(88) Plebani, M.; Nichols, J. H.; Luppa, P. B.; Greene, D.; Sciacovelli, L.; Shaw, J.; Khan, A. I.; Carraro, P.; Freckmann, G.; Dimech, W. Point-of-care testing: state-of-the art and perspectives. *Clinical Chemistry and Laboratory Medicine (CCLM)* **2025**, *63* (1), 35–51.
(89) Anchidin-Norocel, L.; Bosancu, A.; Iatcu, O. C.; Lobiuc, A.; Covasa, M. Real-Time Detection of Heavy Metals and Some Other Pollutants in Wastewater Using Chemical Sensors: A Strategy to Limit the Spread of Antibiotic-Resistant Bacteria. *Chemosensors* **2025**, *13* (9), 352.
(90) Balaram, V. Inductively coupled plasma-tandem mass spectrometry (ICP-MS/MS) and Its applications. *J. ISAS* **2022**, *1* (1), 1–26.
(91) McRae, R.; Bagchi, P.; Sumalekshmy, S.; Fahrni, C. J. In situ imaging of metals in cells and tissues. *Chemical reviews* **2009**, *109* (10), 4780–4827.
(92) Romano, F. Ionic profile of saliva and crevicular gingival fluid as distinctive signature of periodontitis using inductive coupled plasma techniques. **2021**.
(93) McCormick, S. P. The Application of LC-ICP-MS to Study Metal Ion Homeostasis in Biological Systems. 2014.
(94) Zhou, M.; Zhang, X.; Yan, H.; Xing, L.; Tao, Y.; Shen, L. Review on the bioanalysis of non-virus-based gene therapeutics. *Bioanalysis* **2024**, *16* (23-24), 1279–1294.
(95) Mak, C. M.; Lam, C.-W. Diagnosis of Wilson's disease: a comprehensive review. *Critical reviews in clinical laboratory sciences* **2008**, *45* (3), 263–290.
(96) Hare, D. *Elemental bio-imaging: In situ analysis of trace elements in tissue by laser ablation-inductively coupled plasma-mass spectrometry*; University of Technology Sydney (Australia), 2009.
(97) Wang, R. C.; Wang, Z. Precision medicine: disease subtyping and tailored treatment. *Cancers* **2023**, *15* (15), 3837.